Health Groups Hail India's AIDS Drug Patent Move
January 13, 2011
Advocates applauded the Indian Patent Office in Mumbai for its recent rejection of Abbott Laboratories' application to extend patent protections for its second-line AIDS drug Kaletra. The move will facilitate the global supply of cheaper generic versions of the treatment, said Doctors Without Borders, which had challenged Abbott's application. "This news comes as great relief for AIDS treatment programs," said Tido von Schoen-Angerer, head of DWB's global campaign for access to essential medicines. India's generic drug makers supply 80 percent of the cheap AIDS drugs that are available globally, she said. "The decision shows how India's patent law works in favor of public health by granting patents for drugs that are truly innovative," said Keena Menghaney of DWB. "India, the world's leading supplier of affordable medicines, can now supply this drug to patients across the globe who are desperately waiting for treatment," said Tahir Amin, director of Initiatives for Medicines, Access and Knowledge.
Agence France Presse
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)